Worthwhile to whom? Public expectations and the value of lecanemab
Psychiatry and Clinical Neurosciences · 09.11.2026
DOI: 10.1111/pcn.70171 ↗Kurz gefasst
Editorial in der Zeitschrift Psychiatry and Clinical Neurosciences, online erschienen am 09.11.2026. Verfasst von Kenichiro Sato. Beteiligte Einrichtung: Dementia Inclusion and Therapeutics, The University of Tokyo Hospital, Tokyo, Japan. Die Arbeit nennt 3 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Dementia Inclusion and Therapeutics, The University of Tokyo Hospital, Tokyo, Japan.
ORCID-Profile: Kenichiro Sato
Förderung
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
Zitieren
APA
Sato, K. (2026). Worthwhile to whom? Public expectations and the value of lecanemab. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.70171
Vancouver
Sato K. Worthwhile to whom? Public expectations and the value of lecanemab. Psychiatry and Clinical Neurosciences. 2026. doi:10.1111/pcn.70171
BibTeX
@article{Sato2026,
author = {Sato, Kenichiro},
title = {Worthwhile to whom? Public expectations and the value of lecanemab},
journal = {Psychiatry and Clinical Neurosciences},
year = {2026},
doi = {10.1111/pcn.70171}
}
EUVIMED